TriSalus Life Sciences (NASDAQ:TLSI) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of TriSalus Life Sciences (NASDAQ:TLSI) from a sell rating to a hold rating in a report issued on Saturday.

Several other research firms have also commented on TLSI. Zacks Research raised shares of TriSalus Life Sciences from a “strong sell” rating to a “hold” rating in a report on Tuesday, December 16th. Weiss Ratings reissued a “sell (e+)” rating on shares of TriSalus Life Sciences in a report on Monday, December 29th. Finally, Canaccord Genuity Group lowered their target price on TriSalus Life Sciences from $12.00 to $7.00 and set a “buy” rating on the stock in a research note on Friday. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $7.00.

TriSalus Life Sciences Trading Up 3.1%

Shares of NASDAQ TLSI opened at $4.61 on Friday. The company has a 50 day simple moving average of $5.32 and a two-hundred day simple moving average of $5.36. The stock has a market cap of $230.78 million, a price-to-earnings ratio of -2.52 and a beta of 0.42. TriSalus Life Sciences has a 12 month low of $3.42 and a 12 month high of $7.95.

TriSalus Life Sciences (NASDAQ:TLSI) last released its quarterly earnings data on Thursday, March 5th. The company reported ($0.12) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.01. The business had revenue of $13.21 million during the quarter, compared to analyst estimates of $13.20 million. Analysts forecast that TriSalus Life Sciences will post -1.55 EPS for the current year.

Hedge Funds Weigh In On TriSalus Life Sciences

A number of large investors have recently added to or reduced their stakes in TLSI. Police & Firemen s Retirement System of New Jersey acquired a new position in TriSalus Life Sciences during the second quarter worth $29,000. JPMorgan Chase & Co. grew its position in shares of TriSalus Life Sciences by 35,804.8% in the second quarter. JPMorgan Chase & Co. now owns 7,540 shares of the company’s stock valued at $41,000 after purchasing an additional 7,519 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of TriSalus Life Sciences during the second quarter worth about $47,000. Invesco Ltd. purchased a new stake in shares of TriSalus Life Sciences during the fourth quarter worth about $72,000. Finally, Abel Hall LLC acquired a new position in shares of TriSalus Life Sciences during the 4th quarter worth about $73,000. 2.58% of the stock is currently owned by institutional investors and hedge funds.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.